Dr. Apolo on adjuvant pembrolizumab in MIUC

In this video, Andrea B. Apolo, MD, shares key interim findings from the AMBASSADOR Alliance trial (NCT03244384), which was presented at the 2024 Genitourinary Cancers Symposium in San Francisco, California with the study, “AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.” Apolo is a medical oncologist at the National Cancer Institute of the National Institute of Health in Bethesda, Maryland.

Video Transcript:

The study was positive. It met one of its dual primary end points of disease-free survival with a median disease-free survival with adjuvant pembrolizumab of 29 months vs 14 months in the observation arm, with a hazard ratio of 0.69 and a median follow-up of 22 months. We did do PD-L1 testing to see whether PD-L1 status could select the patients that would benefit the most from adjuvant pembrolizumab. We did find that [with] the PD-L1 marker, patients had a better prognosis, but it was not predictive of outcomes with adjuvant pembrolizumab. So, what does this mean for our community? We have a positive trial of adjuvant pembrolizumab. Currently nivolumab is approved in this setting. I think that adjuvant pembrolizumab would be a treatment option also for patients with muscle-invasive disease.

This transcription has been edited for clarity.